Coming December: ASH publishes its late-breaking abstracts. We’ll add the organizations presenting them.

Genentech at ASH 2026

Dec 12–15, 2026 New Orleans, LA ~30k attendees Website

Genentech brings 6 presentations to ASH 2026 in New Orleans, and exhibits at Booth 439. Genentech presents a theater session on long-term follow-up of the POLARIX lymphoma study and hosts a hemophilia A and von Willebrand disease trial showcase. It also supports symposia on bispecifics and ADCs.

OrganizationASH 2026 Attendance
Genentech
South San Francisco, CA
Large pharma
Biotechnology company and member of the Roche Group, with medicines for blood cancers and hemophilia.
Booth
Exhibiting at Booth 439
Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm
Symposium
Fri Dec 11
11:00am–2:00pm
Best Practice Use of Bispecific Antibodies in Non-Hodgkin Lymphoma – A Second Opinion Case Review
Difficult non-Hodgkin lymphoma cases treated or considered for bispecific antibodies, with reviews of recent data, current practice, and ongoing trials.
Lymphoma · New drugs
Symposium
Fri Dec 11
7:00pm–10:00pm
Addressing Community Oncologists’ Questions About BCMA-Directed Antibody-Drug Conjugates and Bispecific Antibodies in Multiple Myeloma – What Clinicians Want To Know
Answers to community oncologists' top questions on B-cell maturation antigen-targeted antibody-drug conjugates and bispecific antibodies in multiple myeloma.
Myeloma · New drugs

Explore the full ASH 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in New Orleans. Leave your work email and we’ll be in touch.

Privacy

Download the full ASH 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Genentech

Tell us what you sell and we’ll find the people at Genentech most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction